The Federal Circuit’s decision last fall in Merck Serono S.A. v. Hopewell Pharma Ventures, Inc., Appeals 2025‑1210, ‑1211 (Fed. Cir. Oct. 30, 2025), reh’g and reh’g en banc denied (Jan. 22, 2026) (link), offers important guidance on the meaning of disclosures “by another” under pre-AIA 35 U.S.C. §§ 102(a) and (e)—a word-pairing that often determines whether a reference qualifies as prior art during prosecution and in litigation (including in inter partes review (IPR) proceedings).* The court’s opinion not only affirmed the Patent Trial and Appeal Board’s conclusion of obviousness in these IPRs but also clarified the legal standard for inventive entity identity, drawing heavily on the CCPA’s decision in In re Land, 368 F.2d 866 (CCPA 1966).Continue Reading The High Hurdles in Disqualifying Prior Art








